Breaking News

Financial Report: Alkermes

April 30, 2014

Manufacturing and royalty revenues down 24% in the quarter

1Q Revenues: $130.2 million (-20%)
1Q Loss: $24.4 million (earnings were $3.0 million in 1Q13)
Comments: Manufacturing and royalty revenues were $111.3 in the quarter, down 24%, with AMPYRA/FAMPYRA down 17% to $20.6 million. Manufacturing and royalty revenues from the company’s antipsychotic franchise, RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION, were $49.6 million, up 9%. VIVITROL sales were $17.1 million, up 17%. Royalty revenue from BYDUREON was $7.7 million, up 60%. R&D expenses were $52.1 million, up 46% reflecting increased investment in the company’s CNS pipeline.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks